SNAP-8

Overview

SNAP-8, also known as Acetyl Glutamyl Heptapeptide-1 or Acetyl Octapeptide-3, is a synthetic octapeptide developed as a topical neuromodulatory ingredient and elongated analog of Argireline (Acetyl Hexapeptide-3). It is designed to reduce the appearance of dynamic facial expression lines through competitive inhibition of the SNARE complex. It is not intended for injection and is used primarily in topical cosmeceutical formulations.

Mechanism of Action

SNAP-8 mimics the N-terminal end of SNAP-25, a key component of the SNARE (SNapREceptor) protein complex responsible for synaptic vesicle fusion and neurotransmitter release. By competing with SNAP-25 for a position in the SNARE complex, SNAP-8 partially destabilizes the complex, reducing acetylcholine release at the neuromuscular junction and attenuating the intensity of facial muscle contractions. This mechanism is pharmacologically analogous to botulinum toxin but operates via competitive inhibition rather than enzymatic cleavage.

Research and Clinical Data

Manufacturer-funded in vivo studies using 10% SNAP-8 in topical formulations demonstrated up to 63% reduction in wrinkle depth around the eye area after 28 days of twice-daily application. Independent research reports more conservative improvements of 10–20%. SNAP-8 is reported to be approximately 30% more active than Argireline in both in vitro and in vivo testing.

Administration

Applied topically at concentrations of 3–10% in serums, creams, and other emulsion formulations. Twice-daily application is recommended; consistent use over 4–8 weeks is required to observe measurable improvements. Effects are not permanent and diminish upon discontinuation.

Potential Adverse Effects

Considered generally safe and well tolerated in clinical testing over 12 weeks. No significant adverse events reported at recommended concentrations. Some formulations may cause mild irritation in sensitive skin types.